CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV)

The feasibility of using oligodeoxynucleotides (ODN) containing unmethylate d CpG motifs as parenteral adjuvants for subunit vaccines against RSV was t ested in BALB/c mice. Compared with immunization with natural F protein ads orbed to aluminum hydroxide (F/AlOH) adjuvant alone, coadministration of F/ AlOH with CpG ODN resulted in statistically significant increases in serum neutralization titers, an enhanced generation of splenic antigen-dependent killer cell precursors, and accelerated clearance of infectious virus from lungs 4 days after challenge. The statistically significant increases in se rum IFN gamma and anti-F protein IgG2a titers, and significantly diminished pulmonary IL-5 and eosinophilia after challenge indicated that CpG ODN enh anced the ability of F/AlOH to elicit type 1 immune responses. F protein-sp ecific serum IgE titers were also reduced. Further analysis of pulmonary in flammatory cells demonstrated an expansion of CD8(+) T cells, relative to t he CD4(+) T cell compartment. The potency of CpG ODN was not adversely affe cted in gene knockout mice devoid of the p35 chain of the IL-12 heterodimer . Taken together, the results suggest a novel formulation for naive recipie nts of F protein-based subunit vaccines that does not result in a type 2 ph enotype. (C) 2001 Elsevier Science Ltd. All rights reserved.